<DOC>
	<DOCNO>NCT01422226</DOCNO>
	<brief_summary>Over last several year , woman choose intrauterine contraception ( IUDs ) meet birth control need . The effectiveness IUDs similar tubal sterilization , overall unintended pregnancy rate le 1 % first year , low failure rate subsequent year . Intrauterine contraception many attribute besides effectiveness ; easily reversible , low side-effect profile , provide long-term solution contraception ( 10 year copper T380 5 year levonorgestrel IUD ) . In addition , use IUD birth control require little on-going effort woman effective offer immediate return fertility removal . The big increase user among nulliparous woman ( woman child ) , due increase awareness safety modern IUDs population , many benefit method . In fact , The copper IUD ( Paragard ) FDA approve use nulliparous woman , American College Obstetricians Gynecologists support use copper levonorgestrel IUDs nulliparous woman . The cervix nulliparous woman small diameter lead difficult uncomfortable IUD insertion . Many provider avoid offer IUDs nulliparas fear procedure difficult , may require cervical dilation , placement paracervical nerve block , placement ultrasound guidance , none standard parous woman . The medication misoprostol prostaglandin E1 analog . Because misoprostol 's know ability cause cervical dilation , family planning provider give nulliparous patient dose drug prior IUD insertion . Misoprostol commonly use dilate cervix similar procedure first trimester abortion , hysteroscopy endometrial biopsy . Its efficacy cervical priming IUD insertion unknown , concern exists uterine contraction cause drug may lead device expulsion displacement . In study , investigator propose ask nulliparous woman undergone contraceptive counseling decide use IUD birth control randomize use misoprostol placebo prior schedule IUD placement .</brief_summary>
	<brief_title>Intra Uterine Device Insertion Nulliparous Women</brief_title>
	<detailed_description>Hypothesis : The prostaglandin E1 analog misoprostol ease insertion intrauterine contraceptive device nulliparous woman . Specific Aim 1 : To evaluate ability place IUD standard fashion , without ancillary measure , nulliparous woman receive misoprostol versus placebo Specific Aim 2 : To evaluate nulliparous woman choose receive IUD whether pre-procedure misoprostol ease pain , compare placebo Specific Aim 3 : To evaluate whether misoprostol reduces rate complication IUD placement , compare placebo Study drug ( misoprostol ) obtain University Utah Health Sciences Center , main study site . The University Utah Health Sciences Center obtain Investigational New Drug ( IND ) exemption FDA order use misoprostol use study . This study part prospective meta-analysis . Deidentified data provide site password protect spreadsheet sent via encrypt , secure email . No identifiable data share site via internet . We complete attachment G , use internet , research do via internet , identifiable data accessible via internet share site involve study . Only deidentified data make available site involve prospective meta-analysis .</detailed_description>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Desires IUD placement 18 year old old negative pregnancy test prior pregnancy beyond 14 6/7 week pelvic inflammatory disease ( PID ) last 3 month current cervicitis contraindication IUD insertion ( see exclusion criterion ) willing followup 68 week standard IUD followup visit Determined clinician appropriate candidate IUD . Active cervical infection current pregnancy prior pregnancy beyond 15 week ' gestation uterine anomaly fibroid uterus copper allergy/Wilson 's disease ( Paragard ) undiagnosed abnormal uterine bleed cervical uterine cancer allergy misoprostol ( study drug )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>IUD</keyword>
	<keyword>contraception</keyword>
	<keyword>nulliparous</keyword>
	<keyword>woman</keyword>
</DOC>